Trends, Controversies and Contradictions in the Management of Gastroesophageal Reflux Disease Patients

References

• Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448–56.
   Google Scholar
• Simpson WG. Gastroesophageal reflux disease and asthma. Arch Intern Med 1995;155:798–803.
   PubMedGoogle Scholar
• Shi G, Kahrilas PJ. Asthma: reflux-induced or reflux-associated? Ital J Gastroenterol Hepatol 1999;31:376–7.
   PubMedGoogle Scholar
• Fraser AG. Gastro-oesophageal reflux and laryngeal symptoms [Review article]. Aliment Pharmacol Ther 1994;8:265–72.
   PubMedGoogle Scholar
• Schroeder PL, Filler SJ, Ramirez B, Lazarchik DA, Vaezi MF, Richter JE. Dental erosions and acid reflux disease. Ann Intern Med 1995;122:809–15.
   PubMedGoogle Scholar
• Kirk AJB. Reflux dyspareunia. Thorax 1986;41:215–6.
   PubMed Web of Science ®Google Scholar
• Mercer CD. Treatment of extraesophageal manifestations of gastroesophageal reflux disease. Can J Gastroenterol 1997;11 Suppl B:103–5.
   Google Scholar
• Hu WHC, Talley NJ. Visceral perception in functional gastrointestinal disorders: disease marker or epiphenomenon? Dig Dis 1996;14:276–88.
   PubMedGoogle Scholar
• Achem SR, Kolts BE, MacMath T, Richter JE, Mohr D, Burton L, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997;42: 2138–45.
   PubMed Web of Science ®Google Scholar
• Cannon RO, Quyyumi AA, Mincemoyer R, Stine AM, Gracely RH, et al. Imipramine in patients with chest pain despite normal coronary angiograms. N Engl J Med 1994;330:1411–7.
   PubMed Web of Science ®Google Scholar
• Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998;42:807–13.
   Google Scholar
• Levin TR, Sperling RM, McQuaid KR. Omeprazole improves peak respiratory flow rate and quality of life in asthmatics with gastroesophageal reflux. Am J Gastroenterol 1998;93:1060–3.
   Google Scholar
• Wiklund I, Bardhan KD, Mueller-Lissner SA, Bigard MA, Bianchi Porro G, Ponce J, et al. Quality of life during acute and intermittent treatment of gastro-oesophageal reflux disease with omeprazole compared with ranitidine. Results from a multicentre trial. Ital J Gastroenterol Hepatol 1998;30:19–27.
   Google Scholar
• Field SK, Sutherland LR. Does medial antireflux therapy improve asthma in asthmatics with gastroesophageal reflux? A critical review of the literature. Chest 1998;114:275–83.
   PubMed Web of Science ®Google Scholar
• Simpson WG. Gastroesophageal reflux disease and asthma. Arch Intern Med 1995;155:798–803.
   PubMedGoogle Scholar
• Gaynor EB. Otolaryngologic manifestations of gastroesophageal reflux. Am J Gastroenterol 1991;86:801–8.
   PubMed Web of Science ®Google Scholar
• Jacob P, Kahrilas PJ, Herzon G. Proximal esophageal pH-metry inpatients with ‘reflux laryngitis’. Gastroenterology 1991;100: 305–10.
   Google Scholar
• Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis. Am J Gastroenterol 1994;96:321–6.
   Google Scholar
• Rokkas T, Anggiansah A, McCullagh M, Owen WJ. Acid perfusion and edrophonium provocation tests in patients with chest pain of undetermined etiology. Dig Dis Sci 1992;37: 1212–6.
   PubMedGoogle Scholar
• Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Festen HPM, Jansen EH, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease. Am J Gastroenterol 1997;92: 1997–2000.
   PubMed Web of Science ®Google Scholar
• Fass R, Fennerty MB, Ofman JJ, Gralnek IM, Johnson C, Camargo E, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115:42–9.
   PubMed Web of Science ®Google Scholar
• Trimble KC, Douglas S, Pryde A, Heading RC. Clinical characteristics and natural history of symptomatic but not excess gastroesophageal reflux. Dig Dis Sci 1995;40:1098–104.
   PubMed Web of Science ®Google Scholar
• McDougall NI, Johnston BT, Collins JSA, McFarland RJ, Love AHG. Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis. Eur J Gastroenterol Hepatol 1997;9: 1161–7.
   Google Scholar
• Dent J, Brun J, Fendrick AM, Fennerty MB, Janssens J, Kahrilas PJ, et al. An evidence-based appraisal of reflux disease management—the Genval Workshop Report. Gut 1999;44 Suppl 2:S1–16.
   PubMed Web of Science ®Google Scholar
• Schindlbeck NE, Klauser AG, Berghammer G, Londong W, Mueller-Lissner SA. Three year follow up of patients with gastrooesophageal disease. Gut 1992;33:1016–9.
   Google Scholar
• McDougall NI, Johnston BT, Kee F, Collins JSA, McFarland RJ, Love AHG. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996;38:481–6.
   PubMed Web of Science ®Google Scholar
• Pace F, Bollani S, Manzionna G, Bianchi Porro G. Audit of reflux oesophagitisat 4 years. Ital J Gastroenterol Hepatol 1998; 30:355–60.
   PubMedGoogle Scholar
• Kuster E, Ros E, Toledo-Pimentel V, Pujol A, Bordas JM, et al. Predictive factors of the long term outcome in gastro-oesophageal reflux disease. Gut 1994;35:8–14.
   Google Scholar
• Hetzel DJ. Controlled clinical trials of omeprazole in the long-term management of reflux disease. Digestion 1992;51 Suppl 1:35–42.
   PubMed Web of Science ®Google Scholar
• Bardhan KD, Mueller-Lissner SA, Bigard MA, Bianchi Porro G, Ponce J, Hosie I, et al. Symptomatic gastro-oesophageal reflux disease: double-blind controlled study of intermittent treatment with omeprazole or ranitidine. Br Med J 1999;318:502–6.
   PubMedGoogle Scholar
• Walker SJ, Baxter ST, Morris AI, Sutton R. Controversy in the therapy of gastro-oesophageal reflux disease—long-term proton pump inhibition or laparoscopic anti-reflux surgery? Aliment Pharmacol Ther 1997;11:249–60.
   PubMedGoogle Scholar
• Heudebert GR, Marks R, Wilcox CM, Centor RM. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis. Gastroenterology 1997;112: 1078–86.
   PubMedGoogle Scholar
• Xia HH, Talley NJ. Helicobacter pylori infection, reflux esophagitis and atrophic gastritis: an unexplored triangle. Am J Gastroenterol 1998;93:394–400.
   PubMedGoogle Scholar
• Pace F, Bianchi Porro G. Gastro-oesophageal reflux and Helicobacter pylori. Ital J Gastroenterol Hepatol 1998;Suppl 3:S289–93.
   Google Scholar
• Richter JE, Falk GW, Vaezi MF. Helicobacter pylori and gastroesophageal reflux disease: the bug may not be all bad. Am J Gastroenterol 1998;93: 1800–2.
   Google Scholar
• Gisbert JP, Pajares JM, Losa C. Helicobacter pylori and gastroesophageal reflux disease: friends or foes? Hepatogastro-enterology 1999;46: 1023–9.
   Google Scholar
• O’Connor HJ. Helicobacter pylori and gastroesophageal reflux disease—clinical implications and management. Aliment Pharmacol Ther 1999;13:117–27.
   PubMedGoogle Scholar
• Rauws EAJ. Should Helicobacter pylori be eradicated before starting long-term proton pump inhibitors? Ital J Gastroenterol Hepatol 1997;29:569–73.
   Google Scholar
• Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom J, Cederberg C, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539–43.
   PubMed Web of Science ®Google Scholar
• Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G, et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37: 743–8.
   PubMed Web of Science ®Google Scholar
• Labenz J, Tillenburg B, Peitz U, Idstrom J-P, Verdù EF, Stolte M, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996;110:725–32.
   Google Scholar
• Labenz J, Tillenburg B, Peitz U, Verdù EF, Stolte M, Borsch G, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997;92:576–8.
   Google Scholar
• Van Herwaarden MA, Samson M, Van Nispen CHM, Mulder PGH, Smout AJP. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. Aliment Pharmacol Ther 1999;13:731–40.
   Google Scholar
• Peters FT, Kuipers EJ, Ganesh S, Sluiter WJ, Klinkenberg-Knol EC, Lamers CB, et al. The influence of Helicobacter pylori on esophageal acid exposure in GERD during acid suppressive therapy. Aliment Pharmacol Ther 1999;13:921–36.
   Google Scholar
• Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease. Am J Gastroenterol 1999;94:884–7.
   PubMedGoogle Scholar
• Hatlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12 months of therapy with omeprazole. Aliment Pharmacol Ther 1997;11:1093–9.
   PubMedGoogle Scholar
• Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999;117:11–6.
   Google Scholar
• Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998;93: 2330–8.
   PubMed Web of Science ®Google Scholar
• Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJA, Bloemena E, Lindeman J, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid-suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995;90:1401–6.
   PubMed Web of Science ®Google Scholar
• Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995;36: 12–6.
   PubMed Web of Science ®Google Scholar
• Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil-cell hyperplasia. Gastroenterology 1997;112: 707–15.
   Google Scholar
• Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HPM, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018–22.
   Google Scholar
• Genta RM. Acid suppression and gastric atrophy: sifting fact from fiction. Gut 1998;43 Suppl 1:35–8.
   PubMed Web of Science ®Google Scholar
• Lundell L, Miettinen P, Myrvold HE, Pedersen SA, Thor K, Andersson A, et al. Lack of effect of acid suppression therapy on gastric atrophy. Gastroenterology 1999;117:319–26.
   PubMed Web of Science ®Google Scholar
• Labenz J. Does Helicobacter pylori affect the management of gastroesophageal reflux disease? [Editorial]. Am J Gastroenterol 1999;94:867–9.
   PubMedGoogle Scholar